Irvine Scientific ships first products from plant in Tokyo

Published: 24-Aug-2011
Packaging Pharmaceutical

Facility produces animal component-free cell culture media

Irvine Scientific has shipped the first products from its industrial cell culture media production facility in Tokyo to customers in Japan and Asia.

The new facility, located in Saitama prefecture, manufactures animal component-free cell culture media in volume requirements ranging from research use to production of biopharmaceuticals and vaccines. The plant has been commissioned and validated as completely animal component free (ACF).

The new facility, which meets the highest quality cGMP standards, currently occupies 1,720m2 and replicates the production and processes used at the Irvine Scientific’s Santa Ana, CA, US manufacturing facility.

The Tokyo site has state-of-the-art formulation and packaging equipment, and uses continuous milling and blending equipment designed and built to Irvine Scientific specifications. There is room for expansion depending on customer demands.

The Tokyo facility capacity doubles Irvine Scientific’s current powder manufacturing capability at Santa Ana and will bring the total capacity at both sites to more than 1.2 million kilos a year.

Irvine Scientific, a member of JX Holdings group, is a designer, manufacturer and distributor of industrial cell culture, cytogenetic, assisted reproductive technology (ART) and specialist media products. It is a large-scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets.

See more

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Read more
Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant

Trending Articles

  1. SGD Pharma partners with Prince Sterilisation Services for pharmaceutical glass packaging The pair have already launched the My Sterinity Nasal platform, a new, versatile sterile vial range within SGD Pharma's My Sterinity RTU platform, using the company's U-Save Type I vials, which are designed to support the growing segment of high-value nasal drug delivery
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258 The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
  4. Lyocontract invests €50m in new freeze-drying facility with Syntegon vial line German CDMO Lyocontract has begun construction of a €50m expansion in Ilsenburg, partnering with Syntegon to install a complete vial filling and lyophilisation line for sterile freeze-dried pharmaceuticals

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant
Ingredients

Irvine introduces NK cell expansion medium for immunotherapy and translational research applications

The first chemically defined, animal component-free cell culture medium for natural killer (NK) cells
Manufacturing

Fujifilm completes acquisition of Irvine Scientific Sales Company and IS Japan

With the acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to <i>in vitro</i> fertilisation and cell therapy
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now